for eMaxHealthCosmetaLife clinical trial results could lead to availability of more natural, longer lasting, cost-effective treatment for deep lines and wrinkles by 2009.
Gel-Del Technologies, a St. Paul, Minnesota based biomedical device company announced that it has concluded clinical trials of CosmetaLife, a dermal filler injection that company officials say holds potential to be a more effective alternative to currently available treatments for deep lines and wrinkles that activates a more natural skin correction.
The company began clinical trials of CosmetaLife, a gel-particle product for injection to correct wrinkles, at six U.S. sites in 2006. The company hopes to introduce the product to the rapidly growing $1 billion cosmetic augmentation market in 2009.
David B. Masters, Ph.D., Gel-Del Technologies founder and president, is the inventor of the technology and its related products.
eMaxHealth welcomes yourcomments and feedback on this story without registration, but keep the comments meaningful please. Links are not accepted.
